Paper Details

  1. Home
  2. Paper Details

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.

Author: CastilloJorge J, MuñozJavier, SarosiekShayna

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review provides guidance on treating ibrutinib-intolerant patients with B-cell malignancies. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is approved for treating B-cell malignancies, but off-target adverse effects can limit treatment tolerance. Approaches to address intolerance include managing side effects with supportive care or dose reductions, switching to alternative BTK inhibitors, or abandoning BTK inhibitors for alternative treatments.
Paper Details　
Original Abstract of the Article :
Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenström macroglobulinemia (WM), relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and chronic lymphocyt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078910/

データ提供：米国国立医学図書館（NLM）

Managing Ibrutinib Intolerance: Navigating the Shifting Sands of Cancer Treatment

Ibrutinib, a powerful drug that targets a key protein involved in B-cell malignancies, has revolutionized the treatment of these cancers. However, some patients experience side effects that limit their ability to tolerate the medication. This study explores strategies for managing ibrutinib intolerance, offering practical guidance for oncologists and patients facing this challenge. It's like finding a new route through a desert landscape, adapting to changing conditions and seeking alternative paths. The researchers suggest various approaches, including managing side effects, switching to alternative drugs, or exploring other treatment options. This comprehensive approach helps patients navigate the complexities of cancer treatment.

Overcoming Ibrutinib Intolerance: Finding New Pathways

Managing ibrutinib intolerance requires a multi-pronged approach, encompassing side effect management, switching to alternative drugs, and exploring other treatment options. This personalized approach ensures that patients receive optimal care and maximize their chances of success in battling B-cell malignancies.

A Journey Through Cancer Treatment: Adapting to the Changing Desert

Think of cancer treatment as a journey through a vast and unpredictable desert. Ibrutinib is a powerful tool, but sometimes the terrain becomes challenging, requiring us to adapt and find alternative paths. This study offers valuable insights for navigating these challenges, ensuring that patients receive the best possible care throughout their journey.

Dr.Camel's Conclusion

This study provides invaluable guidance for managing ibrutinib intolerance in patients with B-cell malignancies. It highlights the importance of personalized approaches to cancer treatment, adapting to changing conditions and exploring alternative paths to ensure optimal patient care. It's like navigating a shifting desert landscape, finding new routes and seeking fresh oases of hope.
Date :
  1. Date Completed 2023-04-10
  2. Date Revised 2023-06-06
Further Info :

Pubmed ID

36723874

DOI: Digital Object Identifier

PMC10078910

Related Literature

Article Analysis
・Side Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.